AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol

businesswire

AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol – NEWSnet – News… as it used to be

More Press Releases

May 29, 2026

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

May 29, 2026

Brayton Purcell LLP Highlights Investigative Report on California’s Silicosis Crisis Linked to Artificial Stone

May 29, 2026

ANU Face, Mind & Body Introduces the Matrix® Skin Renewal Platform: A Revolutionary Approach to Skin Health

May 29, 2026

AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Brayton Purcell LLP Highlights Investigative Report on California’s Silicosis Crisis Linked to Artificial Stone

ANU Face, Mind & Body Introduces the Matrix® Skin Renewal Platform: A Revolutionary Approach to Skin Health

Persuasion Is Not Manipulation – It’s Architecture: ENTELECHY Volume One Brings Aristotle’s Rhetoric to the Age of AI